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The influence of sublingual immunotherapy on several parameters 
of immunological response in children suffering from atopic 
asthma and allergic rhinitis depending on asthma features
Wpływ rocznej immunoterapii podjęzykowej na wybrane parametry odpowiedzi 
immunologicznej u dzieci chorych na astmę atopową i alergiczny nieżyt nosa o różnej 
manifestacji klinicznej
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Abstract
Introduction: The clinical efficacy of sublingual immunotherapy (SLIT) has already been proven and is known to be high. Its in-
fluence on the immunological system of patients suffering from bronchial asthma was also examined. However, it is still unclear 
how the polysensitisation, coexistence of other atopic disease and asthma treatment step influence the response to treatment 
with specific immunotherapy. Herein we evaluate the impact of one-year SLIT on selected markers of immunological response 
depending on different individual and clinical factors of children suffering from atopic asthma and allergic rhinitis.
Material and methods: Twenty-five patients aged 8.1 ± 3.1 years (range 5–15 years), 21 boys and 4 girls, suffering from asth-
ma and allergic rhinitis with polysensitisation to seasonal and non-seasonal allergens, shortlisted for SLIT, were included in the 
study. Th1 cell and Th2 cell percentages, Bcl-2 expression in T cells, and basophil activation after allergen challenge (house dust 
mite and/or grass pollen antigen in solution used for skin prick tests) in peripheral blood were measured using flow cytometry. 
The association between clinical features of asthma and the influence of SLIT on immunological parameters was evaluated with 
exact Fisher test.
Results: No association between the influence of one-year sublingual immunotherapy on immunological system and patients’ 
age, polysensitisation, asthma treatment step, or coexistence of any other atopic diseases was observed. However, an increase 
of the Th1 percentage in children sensitised against more than three allergens was found more often (at the limit of statistical 
significance) than in the group of children sensitised against three or less allergens.
Conclusions: Based on our results, we cannot point to any subgroup isolated in the study, in which the response of the immu-
nological system to sublingual immunotherapy is more satisfactory than any other. Nevertheless, the increase of Th1 cells may 
be more specific for polysensitised children.
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Streszczenie
Wstęp: Kliniczna skuteczność immunoterapii podjęzykowej została już gruntowanie potwierdzona i udokumentowana. Badano 
również jej wpływ na układ odpornościowy chorych na astmę oskrzelową. Jednak do tej pory nie wyjaśniono zależności pomiędzy 
występowaniem alergii wieloważnej, współwystępowaniem innych chorób alergicznych i stopniem terapii astmy a wpływem 
prowadzonej alergenowo-swoistej immunoterapii podjęzykowej. Celem niniejszej pracy była ocena wpływu rocznej immunoterapii 
podjęzykowej na wybrane parametry odpowiedzi immunologicznej w zależności od cech osobniczych i klinicznych cech choroby 
u pacjentów chorych na astmę i alergiczny nieżyt nosa. 
Materiały i metody: Do badania zakwalifikowano 25 dzieci w wieku 8,1 ± 3,1 roku (5–15 lat), 21 chłopców i 4 dziewczynki, 
chorych na astmę oskrzelową i  alergiczny nieżyt nosa z  alergiami poliwalentnymi sezonowymi i  niesezonowymi, które były 
zakwalifikowane do alergenowo-swoistej immunoterapii podjęzykowej. Odsetek limfocytów pomocniczych Th1 i Th2, ekspresję 
antygenu Bcl-2 w limfocytach T oraz aktywację bazofilów pod wpływem swoistych alergenów (zawiesiny antygenów roztoczy 
kurzu domowego i/lub pyłków traw do testów skórnych) badano metodą cytometrii przepływowej. Zależności pomiędzy badanymi 
parametrami oceniano dokładnym testem Fishera.
Wyniki: Nie zaobserwowano istotnych zależności pomiędzy wpływem immunoterapii podjęzykowej na układ odpornościowy 
pacjentów a  wiekiem, występowaniem alergii wieloważnej, stopniem terapii astmy i  współwystępowaniem innych chorób 
alergicznych. Wzrost odsetka limfocytów pomocniczych Th1 pod wpływem immunoterapii podjęzykowej obserwowano nieco 
częściej u dzieci uczulonych na więcej niż 3 alergeny niż u pozostałych. 
Wnioski: Na podstawie badań przeprowadzonych przez autorów pracy nie można wskazać żadnej grupy pacjentów, u których 
można się spodziewać silniejszej mobilizacji układu odpornościowego jako odpowiedzi na prowadzoną immunoterapię podjęzyko-
wą u dzieci chorych na astmę i alergiczny nieżyt nosa. Wzrost odsetka limfocytów pomocniczych Th1 może występować częściej 
u dzieci z alergią poliwalentną. 
Słowa kluczowe: astma, aktywacja bazofilów, układ odpornościowy, immunoterapia podjęzykowa, limfocyty pomocnicze
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Introduction
Allergen-specific immunotherapy is an effec-
tive asthma treatment, acting on the cause rather 
than the symptoms of the disease. Subcutaneous 
immunotherapy (SCIT) has been found to bring 
about serious side effects. An alternative treat-
ment, sublingual immunotherapy (SLIT), causes 
acute systemic reactions very rarely, and its ad-
ministration is simple and safe even for children. 
A drug can be administered at home without su-
pervision of an allergologist. The clinical efficacy 
of SLIT has already been proven, and it was found 
to be high. Its influence on the immunological 
system of patients suffering from asthma has also 
been examined several times [1–8].
Poor asthma control and severity of the dise-
ase have an influence on asthma symptoms and 
the quality of the patient’s life [9]. It was observed 
that the airways of patients with uncontrolled 
asthma contain more inflammation-associated 
cells than do airways of patients with controlled 
disease [10–12]. It is still unclear how polysensi-
tisation, coexistence of other atopic disease, and 
asthma treatment step influence the response to 
specific immunotherapy. In the present paper, 
subgroups of paediatric patients were examined 
to assess whether there is any relation between 
clinical features of asthma and the response of 
the immunological system to the allergen-specific 
sublingual immunotherapy administered for one 
year. Selected analysed parameters included Th1 
and Th2 cell percentages (with regard to classic 
asthma cause aetiology), and apoptotic status of 
Th1 and Th2 cells measured by Bcl-2 expression 
(as it is suggested that prolonged Th2 cell life and 
shortened Th1 cell life may depend on apoptosis 
resistance or susceptibility, respectively). Assess-
ment of Th1 and Th2 Bcl-2 positive cell percenta-
ges was interesting with regard to our previously 
presented results, i.e. one-year sublingual immu-
notherapy significantly influenced an increase of 
Bcl-2 expression in Th1 cells [13]. Assessment of 
basophils activation was performed due to their 
role as effector cells in allergic response to specific 
allergens in sensitised individuals.
The aim of this paper was to evaluate the 
impact of one-year SLIT on selected markers 
of immunological response with regard to the 
dependence of different individual and clinical 




Twenty-five patients aged 8.1 ± 3.1 years 
(5–15 years olds), 21 boys and 4 girls, were inc-
luded in the study. The patients (100%) suffered 
from controlled atopic bronchial asthma and 
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allergic rhinitis. In the study group 15 children 
(60%) had perennial allergic conjunctivitis, 
8 (32%) suffered from atopic dermatitis, 4 (16%) 
had food allergy, and 1 (4%) had otitis media 
with effusion. Atopy was confirmed by skin prick 
test and/or the presence of allergen-specific IgE 
(asIgE). The exact characteristics of the enrolled 
children are presented in Table 1. Table 2 shows 
the frequency of specific IgE of at least class II 
in the examined population. Two children were 
allergic only to Dermatophagoides pteronyssinus 
and Dermatophagoides farinae antigens, another 
Table 1. Characterisation of enrolled children with regard to skin-prick tests, specific IgE results, and vaccine content
Lp asIgE, class II–VI Positive result of skin trick test Content of SLIT vaccine
1. Rye, timothy, D. pteronyssinus, D. farinae, 
birch, alder
D. pteronyssinus, D. farinae, birch, alder, 
grass pollen, grain pollen, hazel, rye
Staloral 300 grass pollen/rye
2. Rye, timothy Grass pollen, rye Staloral 300 grass pollen/rye
3. Timothy, birch, dog’s fur, rye Hazel, birch, alder, grass pollen, dog’s fur, 
rye
Staloral 300 grass pollen/rye
4. Timothy, rye, birch Hazel, birch, alder, grass pollen, mugwort, 
rye, grain pollen, plantain, beech, D. farinae
Staloral 300 grass pollen/rye
5. Rye, timothy, birch, alder, hazel Rye, grass pollen, birch, alder, hazel, grain 
pollen
Staloral 300 grass pollen/birch
6. Rye, grass pollen Rye, grass pollen, grain pollen Staloral 300 grass pollen/rye
7. Hazel, birch, alder, grass pollen, rye, 
plantain, D. farinae, D. pteronyssinus, 
feathers, guinea pig’s, dog’s, cat’s, ham-
ster’s, rabbit’s fur, penicyline, Aspergillus, 
Cladosporium
Hazel, birch, alder, grass pollen, rye, plan-
tain, grain pollen, D. farinae, D. pteronyssi-
nus, Aspergillus, Cladosporium
Staloral 300 grass pollen/rye
8. Rye, grass pollen Hazel, birch, alder, grass pollen, rye, grain 
pollen
Staloral 300 grass pollen/rye
9. Hazel, birch, alder, grass pollen, rye,  
D. farinae, D. pteronyssinus
Hazel, birch, alder, grass pollen, grain  
pollen, rye, Alternaria
Staloral 300 alder/hazel/birch/grass pollen
10. Rye, timothy, birch, alder Birch, alder, grass pollen, grain pollen, rye Staloral 300 grass pollen/rye
11. Rye, timothy, D. farinae, D. pteronyssinus D. farinae, D. pteronyssinus, grass pollen, 
rye
Staloral 300 D. pteronyssinus/D. farinae
12. D. farinae, D. pteronyssinus D. farinae, D. pteronyssinus Staloral 300 D. pteronyssinus/D. farinae
13. D. farinae, D. pteronyssinus D. farinae, D. pteronyssinus Staloral 300 D. pteronyssinus/D. farinae
14. Rye, grass pollen Rye, grass pollen Staloral 300 grass pollen/rye
15. Rye, grass pollen Rye, grass pollen, grain pollen, cat’s fur Staloral 300 grass pollen
16. Rye, timothy Rye, grass pollen Staloral 300 grass pollen/rye
17. Hazel, birch, alder Hazel, birch, alder, grass pollen Staloral 300 alder/hazel/birch/grass pollen
18. Dog’s fur, grass pollen Dog’s fur, grass pollen Staloral 300 grass pollen
19. Hazel, birch, alder, grass pollen, rye, plan-
tain, mugwort, dog’s fur
Hazel, birch, alder, grass pollen, grain  
pollen, rye, plantain, mugwort, dog’s fur
Staloral 300 grass pollen/rye
20. Hazel, birch, alder, mugwort, timothy, rye Hazel, birch, alder, grass pollen, mugwort, 
grain pollen, rye
Staloral 300 alder/hazel/birch/grass pollen
21. Rye, grass pollen, mugwort Rye, grass pollen, Alternaria Staloral 300 grass pollen/rye
22. Hazel, birch, alder, timothy Hazel, birch, alder, grass pollen, grain 
pollen, rye
Staloral 300 grass pollen/rye
23. Hazel, birch, alder, mugwort, timothy, rye, 
dog’s fur, cat’s fur
Hazel, birch, alder, grass pollen, grain pol-
len, rye, mugwort
Staloral 300 alder/hazel/birch/grass pollen
24. Hazel, birch, alder, rye, grass pollen Hazel, birch, alder, grass pollen, grain 
pollen, rye
Staloral 300 grass pollen/rye
25. Hazel, alder, D. farinae, D. pteronyssinus, 
Alternaria, Cladosporium, hamster’s fur
– Staloral 300 D. pteronyssinus/D. farinae
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Table 2. The frequency of specific IgE in the studied group
Allergen Number of patients 
Birch pollen 14 (56%)
Black alder pollen 15 (60%)
Hazel pollen 12 (48%)
Grass pollen 22 (88%)
Rye pollen 19 (76%)
Antigens of house dust mite D. pteronyssinus 7 (28%)
8 were sensitised against grass and tree pollens. 
Nine of the included children were sensitised 
against seasonal and non-seasonal allergens (i.e. 
grass pollens and animal fur, tree pollens, and 
house dust mites). Thirteen children (52%) had 
family history of atopic asthma. Patients were 
treated chronically with:
—  leukotriene receptor antagonists — 11 (44%),
—  antihistamine drugs — 24 (96%),
—  inhalational corticosteroids — 15 (60%),
—  intranasal steroids — 11 (44%),
—  short-acting beta agonists — 25 (100%),
—  long-acting beta agonists — 5 (20%).
Exclusion criteria were a history of other im-
munological or haematological disorders, severe 
infectious diseases, or systemic corticosteroids 
administered less than four weeks before the 
blood collection. 
Evaluation of all studied immunological 
parameters was performed at baseline and after 
12 months of SLIT. As allergen-specific immu-
notherapy, Staloral 300 (Ewopharma AG, France) 
at a concentration of 300 index of biological reac-
tivity/mL (IR/mL) was used (according to Tab. 1). 
The administration included an 11-day induction 
phase followed by a maintenance phase of 240 IR 
of allergen solution two times per week. Nineteen 
children were examined after 12.8 ± 2.6 months 
of SLIT (the parents of six children did not agree 
to test repetition). One child respond with major 
side effects in the maintenance phase (itching in 
the mouth, nausea, sneezing) and the scheme of 
his treatment was modified to administration of 
30 IR of vaccine daily instead of 240 IR weekly, 
administered in two doses.
Flow cytometry
To evaluate the influence of one-year sublin-
gual immunotherapy on the immunological sys-
tem of children with asthma, selected parameters 
in peripheral blood were measured by flow cyto-
metry. Th1 cell percentage was measured by eva-
luation of surface CCR5 antigen on CD4-positive 
lymphocytes, Th2 cell percentage was measured 
by evaluation of surface CRTH2 antigen on CD-
4-positive lymphocytes. Change of Th1 and Th2 
cell percentages within CD4 positive cells after 
one year of sublingual immunotherapy was reco-
gnised as an increase or decrease of appropriate T 
helper cell population. The intracellular expres-
sion of antiapoptotic Bcl-2 protein was measured 
in Th1 cells. Spontaneous basophil activation and 
activation after allergen challenge was evaluated 
by flow cytometric basophil activation test using 
CD203c antigen as a marker of cells activation. 
Allergens (Stallergenes, France) dedicated to 
skin-prick tests were used for the stimulation 
test (Dermatophagoides farinae and Dermato-
phagoides pteronyssinus or/and grass pollens in 
concentration of 0.2 IR/mL in phosphate buffered 
saline). For children sensitised both to house dust 
mites and grass pollen, two basophil activation 
tests with different allergens were performed. 
Decreased number of CD203-positive basophils 
after allergen challenge studied before and after 
one year of SLIT was recognised as a decrease in 
stimulated basophil activation. Flow cytometric 
analysis was performed with a Cytomics FC500 
flow cytometer (Beckman Coulter, USA).
Statistical analysis
The Wilcoxon Match Pair test was used to 
compare non-parametric data from patients before 
and after one year of SLIT. For analysis, percentages 
of T cells (Th1, Th2, Th1-Bcl-2+, and Th2-Bcl-2+ 
cells) and percentage of activated basophils were 
compared. A P value less than 0.05 was conside-
red as significant for all statistical analyses. The 
association between clinical features of asthma and 
influence of SLIT on immunological parameters 
was evaluated with exact Fisher test.
Results
Association between children’s age and 
response of immunological system after  
12 months of sublingual immunotherapy
Children from the studied group were di-
vided into two subgroups, dependent on the 
patient’s age. Into the first subgroup, 13 children 
aged 5–10 years old were enrolled. To the second 
subgroup, 6 children aged 10–15 years old were 
enrolled. Results of analysis are presented in 
Table 3. No association between patients’ age 
and response of immunological system after 12 
months of sublingual immunotherapy was found.
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Table 3. The association between immunological response after 12 months of SLIT and children’s age
Analysed parameter Age 5–10 years old n (%) Age 10.5–15 years old n (%) Statistical 
significance
Increase of Th1 cells percentage 9/13 (69%) 4/6 (66%) p = 1
Decrease of Th2 cells percentage 7/13 (54%) 3/6 (50%) p = 1
Increase of Th1 cells with intracellular expres-
sion of Bcl-2 percentage
9/13 (69%) 4/6 (66%) p = 1
Decrease of spontaneous basophil activation 10/13 (77%) 4/6 (66%) p = 1
Decrease of basophil activation after allergen 
challenge
Number and percentage of tests
12/20 (60%)
Number and percentage of tests
4/8 (50%)
p = 0.69
Table 4. The association between immunological response after 12 months of SLIT and asthma treatment step
Analysed parameter 1 and 2 asthma treatment step 
n (%)




Increase of Th1 cells percentage 8/11 (73%) 4/5 (80%) p = 1.0
Decrease of Th2 cells percentage 8/12 (67%) 2/6 (33%) p = 0.32
Increase of Th1 cells with intracellular  
expression of Bcl-2 percentage
7/11 (64%) 3/5 (60%) p = 1.0
Decrease of spontaneous basophil activation 8/13 (61%) 6/6 (100%) p = 0.13
Decrease of basophil activation after allergen 
challenge
Number and percentage of tests
11/19 (58%)
Number and percentage of tests
5/9 (56%)
p = 1.0
Association between asthma treatment 
step and response of immunological 
system after 12 months of sublingual 
immunotherapy
Children suffering from asthma were divided 
two subgroups, depending on asthma treatment 
step. Asthma treatment steps were classified in 
accordance with the Global Initiative for Asthma 
2014 recommendations regarding necessity of 
reliever medication. Thirteen children with 1 and 
2 asthma treatment steps were enrolled into the 
first subgroup; to the second subgroup, 6 children 
with 3 and 4 asthma treatment steps were enrol-
led. Results of analysis are presented in Table 4. 
No association between asthma treatment step and 
response of immunological system after 12 months 
of sublingual immunotherapy was found.
Association between asthma and allergic 
rhinitis coexistence with other allergic 
diseases and response of immunological 
system after 12 months of sublingual 
immunotherapy
The studied group was divided into two sub-
groups, depending on the allergic diseases that 
coexisted with atopic asthma and allergic rhinitis. 
Eleven children were enrolled into the first sub-
group. They suffered from atopic asthma (AA), 
allergic rhinitis (AR), and allergic conjunctivitis 
(AC). Eight children were enrolled into the second 
group with AA, AR, and AC with coexistence 
of atopic dermatitis (AD), food allergy (FA) and 
others. Results of analysis are presented in Table 5. 
No association between analysed clinical features 
of asthma and response of immunological system 
after 12 months of sublingual immunotherapy 
was found.
Association between polysensitisation  
of children with asthma and response  
of immunological system after 12 months 
of sublingual immunotherapy
Children from the studied group were di-
vided into two subgroups, depending on the 
number of positive reactions in allergen-specific 
IgE test. Into the first subgroup 10 children sen-
sitized to three or fewer allergens were enrolled 
(only seasonal or only non-seasonal). Into second 
subgroup 9 polysensitised children (with more 
than three positive allergen-specific IgE results 
— for seasonal and non-seasonal allergens) 
were enrolled. Results of analysis are presented 
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Table 5.  The association between immunological response after 12 months of SLIT and presence of diseases coexisting 
with asthma and allergic rhinitis
Analysed parameter Children with AA, AR and AC  
n (%)
Children with AA, AR  




Increase of Th1 cells percentage 6/11 (55%) 6/8 (75%) p = 0.58
Decrease of Th2 cells percentage 3/11 (27%) 5/8 (63%) p = 0.18
Increase of Th1 cells with intracellular  
expression of Bcl-2 percentage
5/11 (45%) 6/8 (75%) p = 0.31
Decrease of spontaneous basophil activation 7/11 (64%) 7/8 (88%) p = 0.34
Decrease of basophil activation after allergen 
challenge
Number and percentage of tests
10/15 (67%)
Number and percentage of tests
6/13 (46%)
p = 0.44
AA — allergic asthma, AR — allergic rhinitis, AC — allergic conjunctivitis, AD — atopic dermatitis, FA — food allergy
Table 6.  The association between immunological response after 12 months of SLIT and presence of polysensitisation in 
children suffering from asthma
Analysed parameter ≤ 3 as IgE (number and percenta-
ge of children)




Increase of Th1 cells percentage 4/9 (44%) 9/10 (90%) p = 0.0572
Decrease of Th2 cells percentage 4/9 (44%) 5/10 (50%) p = 1.0
Increase of Th1 cells with intracellular expres-
sion of Bcl-2 percentage
3/9 (33%) 3/10 (30%) p = 1.0
Decrease of spontaneous basophil activation 6/9 (67%) 8/10 (80%) p = 0.63
Decrease of basophil activation after allergen 
challenge
Number and percentage of tests
6/11 (55%)
Number and percentage of tests
11/17 (65%)
p = 0.70
in Table 6. No association between the number 
of positive reactions in as-IgE tests in children 
with asthma and the response of immunological 
system after 12 months of sublingual immu-
notherapy was found. However, an increase in 
the Th1 percentage in children sensitised against 
more than three allergens was found more often 
(at the limit of statistical significance) than in 
group of children sensitised against three or 
less allergens. As we have previously shown, an 
increase in Th1 cell percentage after one year of 
sublingual immunotherapy was significant for 
the entire studied group [13]. Based on the pre-
sent analysis it can be concluded that an increase 
of Th1 cells is more specific for polysensitised 
children.
Discussion
The results of studies all over the world 
are not in agreement according to the effects 
of SLIT with regard to the dependence of the 
type of allergens to which studied groups are 
sensitised. Meta-analyses made in accordance 
with studies performed in children and adults 
indicated greater efficacy of SLIT in the group 
of patients sensitised to house dust mites than 
in groups sensitised to grass pollen or other 
seasonal allergens. On the other hand, another 
meta-analysis performed on the basis of studies 
in children showed than SLIT administered for 
treatment of pollen allergy is more effective than 
in house dust mite sensitisation [14]. There is 
also no compromise regarding administration 
of multi-allergen or single-allergen vaccination. 
Studies from all over the world show sufficient 
efficacy of SLIT with single allergens. Only a li-
mited number of investigations have been per-
formed in SLIT with multi-allergens. The usage 
of multi-allergen SLIT would be more eligible, 
since polysensitisation is more prevalent than 
sensitisation to a  single allergen [15]. Studies 
performed by Emminger et al. showed that sin-
gle-allergen SLIT indicates the same efficacy 
in patients suffering from monosensitisation 
as well as polysensitisation [16]. However, it 
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cannot be clearly defined which of those two 
methods for immunotherapy is more effective 
[14]. A study with 628 adult patients showed 
no difference in efficacy (measured with the 
Rhinocojunctivitis Total Symptom Score) of 
sublingual immunotherapy administered for 
two years between groups of patients suffering 
only from allergic rhinocojunctivitis (ARC) and 
ARC with coexistence of bronchial asthma. The 
same investigation also showed no difference in 
efficacy of SLIT in patients who were mono- and 
polysensitised [17].
We did not observe any difference in SLIT 
action in dependence of patients’ age. Howe-
ver, it has been suggested that the efficacy of 
allergen-specific treatment is higher in adult 
patients than in children [18]. On the other hand, 
Compalati et al. and Han et al. did not find any 
difference in SLIT efficacy between children and 
adults [19, 20].
In the present study we analysed the impact 
of SLIT on the immunological system of patients 
with controlled asthma at different treatment 
steps. We did not find any difference in SLIT im-
pact on immunological system between children 
with 1–2 steps of treatment compared to those 
with 3–4 asthma treatment steps. Other resear-
chers studied the response to SLIT with regard to 
asthma symptoms intensity and found that aller-
gic patients with more severe symptoms during 
the pollen season responded more intensely to 
sublingual immunotherapy than did patients with 
weaker symptoms [21, 22]. 
Our study confirms that there is no difference 
in the influence of sublingual immunotherapy 
on the immunological system of children with 
bronchial asthma and allergic rhinitis depending 
on age, coexistence of other atopic diseases, asth-
ma treatment step, and type of allergy (mono- or 
polysensitisation). Based on our results we can-
not point to any subgroup of children in whom 
response of immunological system to sublingual 
immunotherapy is more satisfactory than any 
other. The increase of Th1 percentage in children 
sensitised against more than three allergens was 
found more often than in the group of children 
sensitised against three or fewer allergens; never-
theless, the number of patients in the compared 
subgroups was probably too small to reach stati-
stical significance. It should also be emphasised 
that the efficacy of SLIT and its impact on the 
immunological system is mainly dependent on 
the time (at least three years) and regularity of 
administration [8], as well as on the dosage of 
vaccine administered [17].
Acknowledgments
This project is co-financed by PhD grant 
1WW/NK1D/09 funded by the Medical Univer-
sity of Warsaw and a Mazovia PhD Scholarship 
(2008–2009) funded by Mazovia Voivodeship, 
Polish Government.
Conflict of interest
The authors declare no conflict of interest.
References:
1. Antunez C., Mayorga C., Corzo J.L., Jurado A., Torres M.J. Two 
year follow-up of immunological response in mite-allergic 
children treated with sublingual immunotherapy. Comparison 
with subcutaneous administration. Pediatr. Allergy Immunol. 
2008; 19: 210–218.
2. Bahceciler N.N., Arikan C., Taylor A. et al. Impact of sublin-
gual immunotherapy on specific antibody levels in asthmatic 
children allergic to house dust mites. Int. Arch. Allergy Immu-
nol. 2005; 136: 287–294.
3. Bohle B., Kinciyan T., Gerstmayr M., Radakovics A., Jahn
-Schmid B., Ebner C. Sublingual immunotherapy induces 
IL-10-producing T regulatory cells, allergenspecific T-cell tole-
rance, and immune deviation. J. Allergy Clin. Immunol. 2007; 
120: 707–713.
4. Burastero S.E., Mistrello G., Falagiani P. et al. Effect of sublin-
gual immunotherapy with grass monomeric allergoid on aller-
gen-specific T-cell proliferation and interleukin 10 production. 
Ann. Allergy Asthma Immunol. 2008; 100: 343–350.
5. Cosmi L., Santarlasci V., Angeli R. et al. Sublingual immu-
notherapy with Dermatophagoides monomeric allergoid down
-regulates allergen-specific immunoglobulin E and increases 
both interferon gamma and interleukin-10-production. Clin. 
Exp. Allerg. 2006; 36: 261–272.
6. Leatherman B.D., Owen S., Parker M. et al. Sublingual Immu-
notherapy: Past, present, paradigm for the future? A  review of 
the literature. Otolaryngol. Head Neck Surg. 2007; 136 (suppl. 3): 
S1–S20.
7. Ott H., Sieber J., Brehler R. et al. Efficacy of grass pollen su-
blingual immunotherapy for three consecutive seasons and 
after cessation of treatment: the ECRIT study. Allergy 2009; 
64: 179–186.
8. Wahn U., Tabar A., Kuna P. et al. SLIT Study Group: Efficacy 
and safety of 5-grass pollen sublingual immunotherapy tablets 
in pediatric allergic rhinoconjunctivitis. J. Allergy Clin. Immu-
nol. 2009; 123: 160–166.
9. Gonzalez-Barcala F.J., de la Fuente-Cid R., Tafalla M., Nuevo 
J., Caamaño-Isorna F. Factors associated with health-related 
quality of life in adults with asthma. A cross-sectional study. 
Multidiscip. Respir. Med. 2012; 7: 32. doi: 10.1186/2049- 
-6958-7-32
10. He X.Y., Simpson J.L., Wang F. Inflammatory phenotypes in 
stable and acute childhood asthma. Paediatr. Respir. Rev. 2011; 
12: 165–169.
11. Bime C., Nguyen J., Wise R.A. Measures of asthma control. 
Curr. Opin. Pulm. Med. 2012; 18: 48–56.
12. Al-Muhsen S., Johnson J.R., Hamid Q. Remodeling in asthma. 
J. Allergy Clin. Immunol. 2011; 128: 451–462.
13. Ciepiela O., Zawadzka-Krajewska A., Kotuła I., van Overveld F., 
Kulus M., Demkow U. Sublingual immunotherapy for asthma: 
affects T-cells but does not impact basophil activation. Pediatr. 
Allergy Immunol. Pulmonol. 2014; 27: 17–23.
14. Incorvaia C., Di Rienzo A., Celani C., Makrì E., Frati F. Treating 
allergic rhinitis by sublingual immunotherapy: a review. Ann. 
Ist. Super Sanita 2012; 48: 172–176.
15. Calderón M.A., Cox L., Casale T.B., Moingeon P., Demoly P. 
Multiple-allergen and single-allergen immunotherapy stra-
Pneumonologia i Alergologia Polska 2014, tom 82, nr 6, strony 503–510 
510 www.pneumonologia.viamedica.pl
tegies in polysensitized patients: looking at the published 
evidence. J. Allergy Clin. Immunol. 2012; 129: 929–934.
16. Emminger W., Durham S.R., Riis B., Maloney J., Nolte H. The 
efficacy of single-grass-allergen-immunotherapy-tablet treat-
ment in mono- and multi-sensitized allergic rhinitis patients: 
findings from a post hoc analysis. J. Allergy Clin. Immunol. 
2009; 123 (suppl.): S75.
17. Didier A., Malling H.J., Worm M. et al. Optimal dose, effica-
cy, and safety of once daily sublingual immunotherapy with 
a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy 
Clin. Immunol. 2007; 120: 1338–1345.
18. Di Bona D., Plaia A., Scafidi V. et al. Efficacy of sublingual 
immunotherapy with grass allergens for seasonal allergic rhi-
nitis: a systematic review and meta-analysis. J. Allergy Clin. 
Immunol. 2010; 126: 558–566.
19. Compalati E., Passalacqua G., Bonini M., Canonica G.W. The 
efficacy of sublingual immunotherapy for house dust mites 
respiratory allergy: results of a GA2LEN meta-analysis. Allergy 
2009; 64: 1570–1579.
20. Han D.H., Choi Y.S., Lee J.E. et al. Clinical efficacy of sublin-
gual immunotherapy in pediatric patients with allergic rhinitis 
sensitized to house dust mites: comparison to adult patients. 
Acta Otolaryngol. 2012; 132 (suppl. 1): S88–S93.
21. Malling H.J., Montagut A., Melac M. et al. Efficacy and safety 
of 5-grass pollen sublingual immunotherapy tablets in patients 
with different clinical profiles of allergic rhinoconjunctivitis. 
Clin. Exp. Allergy 2009; 39: 387–393.
22. Viswanathan R.K., Busse W.W. Allergen immunotherapy in al-
lergic respiratory diseases: from mechanisms to meta-analyses. 
Chest 2012; 141: 1303–1314.
